Related Experiment Video
Updated: Feb 7, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer
John S P Yuen1, Valentine M Macaulay
1Weatherall Institute of Molecular Medicine, University of Oxford, IGF Group, Molecular Oncology Laboratories, Headley Way, Headington, Oxford OX3 9DS, UK.
Background:
The type 1 insulin-like growth factor receptor (IGF1R) plays a critical role in transformation, invasion and apoptosis protection, and is an attractive cancer treatment target.
Objective:
To review IGF1R antibodies and kinase inhibitors that are in preclinical and clinical development, and to discuss questions that will influence the success of this approach in clinical practice.
Methods:
This review is drawn from published literature, meeting abstracts and online resources.
Results/Conclusion:
IGF1R blockade is generally well tolerated although it can induce hyperglycaemia. Single-agent activity has been documented in Ewing's sarcoma but not thus far in common solid tumours. Key issues include identification of factors that influence sensitivity to IGF1R blockade, and how most effectively to combine IGF1R inhibitors with other treatments.
Insights
IGF1R inhibitors show promise in cancer therapy, are well-tolerated, and effective in Ewing's sarcoma. Further research is needed to identify sensitive patient populations and optimal combination strategies for common solid tumors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The type 1 insulin-like growth factor receptor (IGF1R) is crucial for cancer cell growth, invasion, and survival.
- IGF1R is a significant target for novel cancer therapeutics.
Purpose of the Study:
- To review IGF1R antibodies and kinase inhibitors in development.
- To discuss factors influencing the clinical success of IGF1R-targeted therapies.
Main Methods:
- Literature review of published studies.
- Analysis of meeting abstracts and online resources.
Main Results:
- IGF1R blockade is generally well-tolerated, with hyperglycemia as a notable side effect.
- Single-agent activity observed in Ewing's sarcoma, but not yet in common solid tumors.
- Key challenges include identifying predictive biomarkers and optimal combination therapies.
Conclusions:
- IGF1R-targeted therapies are promising but require further investigation for broader efficacy.
- Identifying patient sensitivity and effective combination strategies are critical for clinical success.
More Related Videos
09:16Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Related Concept Videos
Factors Influencing Microbial Growth: pH
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Insulin: The Receptor and Signaling Pathways
Types of Receptors: Internal Receptors
Similar to membrane-bound receptors, the binding of a ligand to the intracellular receptor of causes a conformational change in the...
Types of Receptors: Cell Surface Receptors
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...